Dytfeld D, Wróbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol 2026; 13: e241–53—Anna Puła's affiliations should have been “Medical University of Lodz, Lodz, Poland” and “University of Chicago, Chicago, IL, USA”. Agnieszka Druzd-Sitek's and Prof Jan Walewski's affiliation should have been “Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw”.
Dytfeld D, Wróbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol 2026; 13: e241–53—Anna Puła's affiliations should have been “Medical University of Lodz, Lodz, Poland” and “University of Chicago, Chicago, IL, USA”. Agnieszka Druzd-Sitek's and Prof Jan Walewski's affiliation should have been “Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw”.